Webinar 1: Advances in AI – generative AI to support regulatory submission
The Cancer Drug Development Forum (CDDF) is pleased to present our live webinar series on “AI and Big Data in Oncology Drug Development.” This series is designed to explore the transformative impact of artificial intelligence and big data on the field of oncology. Featuring leading experts, the webinars will delve into the latest advancements and applications of AI in cancer drug discovery, development, and regulatory processes. Join us to uncover how these cutting-edge technologies are accelerating innovation, improving efficiency, and enhancing outcomes in oncology drug development.
First Webinar: Advances in AI – Generative AI to Support Regulatory Submission
The inaugural webinar in our series, “Advances in AI – Generative AI to Support Regulatory Submission” will take place on 29 October 2024 at 17:00 CET. This webinar will feature a lecture given by Dr Katrin Rupalla (Johnson & Johnson) and will be followed by a panel discussion moderated by Prof. Axel Glasmacher (CDDF) and Prof. Jaap Verweij (CDDF).
WEBINAR OUTLINE
Coming soon
Agenda: (CET time zone)
17:00 – 17:05 Introduction – Prof. Axel Glasmacher (CDDF, DE)
17:05 – 17:30 Lecture by Dr Katrin Rupalla (Johnson & Johnson, NL)
17:30 – 18:00 Panel discussion – moderated by Prof. Jaap Verweij (CDDF, NL) and Prof. Axel Glasmacher (CDDF, DE)
Dr Katrin Rupalla
Katrin Rupalla has extensive experience in drug development and held various leadership roles in the Pharma and biotech industry. She currently serves as the Global Head of Regulatory Affairs at J&J Innovative Medicines, USA.
Prior to joining J&J in 2023, she was an independent board member where she was responsible for governance and strategic direction of 4D Pharma, Ambrx and Zversa, incl. oversight of three IPO and SPAC acquisitions. She also is one of the Founders and previous CEO of Ymmunobio, Switzerland a preclinical stage biotech company.
Previous senior leadership positions include Senior Vice President, Global Head Regulatory Affairs & R&D Quality, at Lundbeck SA, DK and Vice President Global Head Oncology Regulatory Science, Vice President Head China Development, and Vice President EU Regulatory Science at BMS where she led large regulatory and R&D teams.
She obtained her degree in pharmacy and her PhD in CNS Pharmacology at the Philipps University Marburg, Germany. In addition, she has an MBA from Jones International University, USA and a NED Diploma from Financial Times